Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Aug

Today In Oncology

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Related Videos

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

The Interventional Pharmacoeconomic Toolbox Panel Discussion

When Diagnosis Waits: Lung Cancer, PET Access, and Global Oncology

Phase I Trial Evaluates Allogeneic CD70-Targeted CAR T-Cell Therapy in Advanced Renal Cell Carcinoma

Combination Regimen Prolongs PFS in dMMR-MSI-H Metastatic Colorectal Cancer

CKM Syndrome Associated With Increased, Stage-Specific Cancer Risk, Study Finds

Population-Based MGUS Screening Enables Earlier Detection of Multiple Myeloma Without Increasing Psychological Distress